Trifluoroacetic acid → HCID 86727486, compound
Reaction equation
C(OC([N:8]1[CH2:11][CH:10]([NH:12][C:13]2[CH:14]=[C:15]3[C:24](=[CH:25][C:26]=2[O:27][CH2:28][C:29]2[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=2)[O:23][CH2:22][C:21]2[N:16]3[CH:17]([CH3:36])[C:18](=[O:35])[NH:19][N:20]=2)[CH2:9]1)=O)(C)(C)C.[C:37]([OH:43])([C:39]([F:42])([F:41])[F:40])=[O:38]>C(Cl)Cl>[F:40][C:39]([F:42])([F:41])[C:37]([OH:43])=[O:38].[NH:8]1[CH2:11][CH:10]([NH:12][C:13]2[CH:14]=[C:15]3[C:24](=[CH:25][C:26]=2[O:27][CH2:28][C:29]2[CH:34]=[CH:33][CH:32]=[CH:31][CH:30]=2)[O:23][CH2:22][C:21]2[N:16]3[CH:17]([CH3:36])[C:18](=[O:35])[NH:19][N:20]=2)[CH2:9]1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
A solution of 3-(7-benzyloxy-4-methyl-3-oxo-2,3,4,10-tetrahydro-9-oxa-1,2,4a-triaza-phenanthren-6-ylamino)-azetidine-1-carboxylic acid tert-butyl ester (0.028 g, 0.057 mmol) in TFA (0.5 mL) and DCM (3 mL) was stirred at rt for 2 h. The solvent was removed in vacuo and the residue was purified by preparative HPLC (Table 3, Method 18) to give 6-(azetidin-3-ylamino)-7-benzyloxy-4-methyl-2,10-dihydro-9-oxa-1,2,4a-triaza-phenanthren-3-one trifluoroacetic acid (0.013 g, 58%). LC/MS (Table 1, Method 5) Rt=2.201 min; MS m/z: 394 [M+H]+
Workup
- customThe solvent was removed in vacuo
- customthe residue was purified by preparative HPLC (Table 3, Method 18)
Sources & evidence
- ORD record
- ord-db6ad1401f6a48d097a593bfa285d514
- Source dataset
- uspto-grants-2015_08
- Patent number
- US09115151B2
Reaction notes
Loading…